We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Brain Cancer

Journal Scan / Research · December 02, 2021

Trabectedin Increases Toxicity Without Improving PFS and OS in Patients With Meningioma



Additional Info

Disclosure statements are available on the authors' profiles:

Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Neuro-oncology 2021 Oct 21;[EPub Ahead of Print], M Preusser, A Silvani, E Le Rhun, R Soffietti, G Lombardi, JM Sepulveda, P Brandal, L Brazil, A Bonneville-Levard, V Lorgis, E Vauleon, J Bromberg, S Erridge, A Cameron, F Lefranc, PM Clement, S Dumont, M Sanson, C Bronnimann, C Balaná, N Thon, J Lewis, MJ Mair, P Sievers, J Furtner, J Pichler, J Bruna, F Ducray, JC Reijneveld, C Mawrin, M Bendszus, C Marosi, V Golfinopoulos, C Coens, T Gorlia, M Weller, F Sahm, W Wick

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading